Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.
There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.
Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.
The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.
The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.
Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.